Intensive Medicines Monitoring Project of Palonosetron Hydrochloride Capsules (Ruo Shan®)

Overview

Observe palonosetron hydrochloride capsules'(Ruo Shan®) safety and efficacy information in the real world using.

Full Title of Study: “Intensive Medicines Monitoring Project of Palonosetron Hydrochloride Capsules”

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Prospective
  • Study Primary Completion Date: March 8, 2018

Detailed Description

Observe palonosetron hydrochloride capsules'(Ruo Shan®) safety and efficacy information in the real world using. 1. Observe the adverse effects of palonosetron hydrochloride capsules(Ruo Shan®) that we already known, and whether there is any new adverse effects.Observe the incidence and the situation of adverse effects. Pay attention to the adverse effects in special groups, like pregnant women, children, elderly patients, and patients with liver and kidney dysfunction. Observe other safety issues related to drug using method, drug packaging method and drug quality. [Time Frame: A period between the first day of using Palonosetron Hydrochloride Capsules (Ruo Shan®) to the fifth day] Secondary Outcome Measures: 2. Furtherly clarify the efficacy of palonosetron hydrochloride capsules, and the widely used population characteristics, and clinical using features of palonosetron hydrochloride capsules. [Time Frame: A period between the first day of using Palonosetron Hydrochloride Capsules (Ruo Shan®) to the fifth day]

Interventions

  • Drug: palonosetron hydrochloride capsules
    • Collect all the patients’ safty and efficacy data as long as they use palonosetron hydrochloride capsules(Ruo Shan®) .Specific methods of using the drugs are not limited .

Arms, Groups and Cohorts

  • palonosetron palonosetron hydrochloride
    • A continuous sequence of patients using palonosetron palonosetron hydrochloride capsules(Ruo Shan®)

Clinical Trial Outcome Measures

Primary Measures

  • Report the palonosetron hydrochloride capsules'(Ruo Shan®) safety information in the real world using.
    • Time Frame: A period between the first day of using Palonosetron Hydrochloride Capsules (Ruo Shan®) to the fifth day
    • Report the adverse effects of palonosetron hydrochloride capsules(Ruo Shan®) that we already known; Report if there is any new adverse effects; Report the incidence and the situation of the above adverse effects; Report the adverse effects in special groups, like pregnant women, children, elderly patients, and patients with liver and kidney dysfunction; Report other safety issues related to drug using method, drug packaging method and drug quality.

Secondary Measures

  • Report the efficacy of palonosetron hydrochloride capsules.
    • Time Frame: A period between the first day of using Palonosetron Hydrochloride Capsules (Ruo Shan®) to the fifth day
    • Report the control condition of nausea and vomiting.
  • Report the widely used population characteristics.
    • Time Frame: A period between the first day of using Palonosetron Hydrochloride Capsules (Ruo Shan®) to the fifth day
    • Report the patients’ disease, age, treatment, and chemotherapy drugs.
  • Report the clinical using features of palonosetron hydrochloride capsules.
    • Time Frame: A period between the first day of using Palonosetron Hydrochloride Capsules (Ruo Shan®) to the fifth day
    • Report the Using does,time,and frequency of palonosetron hydrochloride capsules,and the concomitant drugs .

Participating in This Clinical Trial

Inclusion Criteria

  • Use palonosetron hydrochloride capsules(Ruo Shan®) .Specific methods of using the drugs are not limited . – Elderly patients do not need to adjust the dosage of the drug. – Children using the drug and dose adjustment need to be evaluated by the doctor. – Pregnant and lactating patients using the drug need to be evaluated by the doctor. – 5-HT3RA allergic patients do not recommend the use of this drug. Exclusion Criteria:

  • All situations that the doctor think it is not suitable to use palonosetron hydrochloride capsules(Ruo Shan®) .

Gender Eligibility: All

Minimum Age: N/A

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Cttq
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • qin shu kui, Study Chair, The 81st Hostital of PLA
  • Overall Contact(s)
    • zheng bo, 18136659876, jtuu@163.com

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.